Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial

Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/85830

Scopus	Web of Science®	Altmetric
Citations
?	?

Type:	Journal article
Title:	Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial
Author:	van Meurs, H. Tajik, P. Hof, M. Vergote, I. Kenter, G. Mol, B. Buist, M. Bossuyt, P.
Citation:	European Journal of Cancer, 2013; 49(15):3191-3201
Publisher:	Elsevier
Issue Date:	2013
ISSN:	0959-8049 1879-0852
Statement of Responsibility:	Hannah S. van Meurs, Parvin Tajik, Michel H.P. Hof, Ignace Vergote, Gemma G. Kenter, Ben Willem J. Mol, Marrije R. Buist, Patrick M. Bossuyt
Abstract:	Abstract not available
Keywords:	Ovarian cancer; treatment selection; additive interaction; chemotherapy; surgery
Rights:	© 2013 Elsevier Ltd. All rights reserved.
DOI:	10.1016/j.ejca.2013.06.013
Published version:	http://dx.doi.org/10.1016/j.ejca.2013.06.013
Appears in Collections:	Aurora harvest 2 Obstetrics and Gynaecology publications

Files in This Item:

There are no files associated with this item.

Show full item record

Adelaide Research & Scholarship